Clinical trials: Rivaroxaban
Peripheral Arterial Disease
Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.
Rationale: Peripheral arterial disease (PAD) is a common presentation of atherosclerosis. For the prevention of adverse events related to arterial thrombosis in PAD patients, clopidogrel is recommended.
- Trial name
- GENPAD (NCT04619927)
- Testing
- Direct CYP2C19 genotyping, CYP2C19 genotyping at the end of the study, Poor metabolisers
- Where
- 11 sites in Netherlands
- Volunteers
- 2,276 people
- Sponsor
- Radboud University Medical Center
Peripheral Arterial Disease (PAD), Amputation
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore…
- Conditions
- Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis)
- Trial name
- NCT07613840
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 484 people
- Sponsor
- Massachusetts General Hospital
Scleroderma, Systemic, Sclerosis, Systemic
Pragmatic Clinical Trials in Scleroderma
Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by autoantibodies, fibrosis and microvascular injury and endothelial cell activation that results in vascular damage.
- Trial name
- PCTS (NCT03610217)
- Testing
- Interstitial lung disease induction algorithm, Pulmonary arterial hypertension algorithm, Raynaud's phenomenon algorithm
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- University of West London
Venous Thromboembolism
VTE Prevention Following Total Hip and Knee Arthroplasty
Consented patients undergoing elective total hip and total knee arthroplasty will be randomized to receive either aspirin alone or aspirin and rivaroxaban for prevention of venous thromboembolism.
- Trial name
- EPCATIII (NCT04075240)
- Testing
- Rivaroxaban 10 MG and acetylsalicylic acid 81 mg, acetylsalicylic acid 81 mg
- Where
- Canada
- Volunteers
- 5,429 people
- Sponsor
- Sudeep Shivakumar
Venous Thromboembolism
Xarelto Regulatory Post-Marketing Surveillance
This study is to identify the following problems and questions with respect to the safety and effectiveness of Xarelto in comparison with other pharmacologic agents in the prophylaxis of venous thromboembolism (VTE) in a large…
- Trial name
- NCT01029743
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)
- Where
- South Korea
- Volunteers
- 3,388 people
- Sponsor
- Bayer
Venous Thromboembolism
Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty
In this study the investigators want to look at whether using aspirin instead of rivaroxaban (after initial treatment with rivaroxaban) works as well at preventing blood clots while also reducing risk of bleeding and is more cost…
- Trial name
- EPCAT II (NCT01720108)
- Testing
- rivaroxaban and ASA
- Where
- Canada
- Volunteers
- 3,426 people
- Sponsor
- David Anderson
Atrial Fibrillation
Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation
The DaRe2 approach (healthcare Data for pragmatic clinical Research in the NHS - primary 2 secondary) is designed to operationalise efficient, nationwide, primary care approaches for randomised trials embedded within the UK…
- Trial name
- DaRe2THINK (NCT04700826)
- Testing
- Direct Oral Anticoagulants
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- University of Birmingham
Non-valvular Atrial Fibrillation (NVAF), Chronic Kidney Disease (CKD)
Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry
The multicenter registry will collect clinical data from 1600 patients with non valvular atrial fibrillation (NVAF) and chronic kidney disease (eGFR 15-49 mL/min per 1.73 m2).
- Trial name
- XARENO (NCT02663076)
- Where
- 121 sites in Austria, Belgium and 3 more
- Volunteers
- 1,700 people
- Sponsor
- GWT-TUD GmbH
Total Knee Arthroplasty, Venous Thromboembolism
Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
Yes. For these two fields, I would enter the following in English, based on your study protocol. 1. Brief Summary Copy and paste: This study aims to compare three thromboprophylaxis regimens in adults undergoing primary total…
- Trial name
- DOLOTHROK (NCT07869615)
- Testing
- Apixaban, Rivaroxaban, Enoxaparin (LMWH)
- Where
- Tunisia
- Volunteers
- 138 people
- Sponsor
- Military Hospital of Tunis
Acute Coronary Syndrome
To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome
Direct-acting oral anticoagulants (DOACs) have provided benefits to patients requiring anticoagulation for certain diseases by decreasing the burden of subcutaneous injections and the requirement for frequent monitoring through…
- Trial name
- ACCP (NCT05573958)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet, Clopidogrel tablet, Aspirin tablet
- Volunteers
- 90 people
- Sponsor
- Sarmad Zahoor
Atrial Fibrillation
Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).
- Trial name
- NCT00494871
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- 165 sites in Japan
- Volunteers
- 1,280 people
- Sponsor
- Bayer
Type 2 Diabetic Patients
Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk
Study to investigate microvascular and antiinflammatory effects of Rivaroxaban compared to low dose aspirin in type 2 diabetic patients.
- Trial name
- MicroVasc-DIVA (NCT02164578)
- Testing
- Rivaroxaban, Aspirin
- Where
- 5 sites in Germany
- Volunteers
- 179 people
- Sponsor
- GWT-TUD GmbH
Multiple Myeloma, Venous Thromboembolism (VTE)
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
The goal of this clinical trial is to compare the efficacy and safety of aspirin versus rivaroxaban for thromboprophylaxis in newly diagnosed multiple myeloma patients receiving immunomodulatory drug (IMiD)-based therapy.
- Trial name
- NCT07907211
- Testing
- Aspirin, Rivaroxaban
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chen Lijuan
Venous Thromboembolism
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis
The purpose of this study is to determine the optimal dose of BAY 59-7939 and to compare the safety and effectiveness of this new drug with the standard way of treatment of deep vein thrombosis (heparin infusion plus one of the…
- Trial name
- NCT00395772
- Testing
- Xarelto (Rivaroxaban, BAY59-7939), (LMW) Heparin + Vitamin K Antagonist
- Where
- 78 sites in United States, Australia and 11 more
- Volunteers
- 543 people
- Sponsor
- Bayer
Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous…
- Conditions
- Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders, Anticoagulation Treatment, Anticoagulant Therapy
- Trial name
- NCT06947707
- Where
- China
- Volunteers
- 1,486 people
- Sponsor
- Xuanwu Hospital, Beijing
Atrial Fibrillation
Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention
The main objective of this pilot study is to investigate the protein / peptide plasma profiles before and after treatment with a direct anti-Xa (activated Factor 10) in patients with non-valvular atrial fibrillation to better…
- Trial name
- Naco_Nîmes (NCT02273700)
- Testing
- Rivaroxaban
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Uterine Hemorrhage, Cardiovascular Diseases
A Study on Abnormal Menstrual Bleeding in Chinese Women of Childbearing Age Taking Antithrombotic Drugs After Cardiovascular Surgery
This study aims to investigate uterine bleeding during menstruation in women taking antithrombotic medications after cardiac surgery.
- Conditions
- Uterine Hemorrhage, Cardiovascular Diseases, Antithrombotic Drugs
- Trial name
- NCT07870941
- Testing
- antithrombotic drugs
- Where
- China
- Volunteers
- 1,308 people
- Sponsor
- Shanghai Zhongshan Hospital
Venous Thromboembolism
Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Patients undergoing surgery, especially hip and knee surgery, are at high risk for VTE. The administration of drugs for thromboprophylaxis, such as heparins, significantly lowers that risk, but heparins have to be applied by…
- Trial name
- ODIXa-HIP2 (NCT00398905)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 61 sites in Austria, Belgium and 11 more
- Volunteers
- 726 people
- Sponsor
- Bayer
Severe Bleeding, Urgent Surgery
Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists
Patients treated with Vitamin K antagonists (VKA) or direct oral anticoagulants as Rivaroxaban, Apixaban, Edoxaban or Dabigatran, who experience severe bleeding and/or need urgent interventions/operations that cannot wait are…
- Trial name
- RADOA (NCT01722786)
- Where
- Germany
- Volunteers
- 272 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Atrial Fibrillation (AF), VTE
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
PAUSE 2 study is a prospective, open-label, blinded-endpoint non-inferiority RCT of PAUSE vs. ASRA management in DOAC treated high risk patients with AF/VTE who need elective high bleed risk surgery/procedure and/or any procedure…
- Trial name
- PAUSE 2 RCT (NCT06957366)
- Testing
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 920 people
- Sponsor
- McMaster University